Phase I/II Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 28 Mar 2013
At a glance
- Drugs Dasatinib (Primary) ; Docetaxel (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 31 Aug 2018 Biomarkers information updated
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Dec 2012 Planned end date changed from 1 Nov 2012 to 1 May 2013 as reported by ClinicalTrials.gov record.